Drug Trial Radar · NCT02903524
Doxorubicin Hydrochloride Liposome Injection Combination With Cyclophosphamide vs Pirarubicin Combination With Cyclophosphamide in Patients With Locally Advanced Breast Cancer
Last checked: Nov 20, 2026Latest source record: Sep 16, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
300
Planned (sponsor's estimate)
Start
Sep 2016
Primary completion
Sep 2018
Study completion Dec 2018
Sponsor
- Lead sponsor
- Hebei Medical University Fourth HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 16, 2016
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Evaluate the efficacy and safety of Doxorubicin Hydrochloride Liposome Injection Plus Cyclophosphamide Compared to Pirarubicin Plus Cyclophosphamide as Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer Patients
Conditions
- Breast Cancer
Interventions
Doxorubicin Hydrochloride Liposome injection and cyclophosphamideDrug
pirarubicin and cyclophosphamideDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- pathological complete responseTime frame: until the completion of 4 cycles (each cycle is 21 days) of chemotherapy
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.